{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T01:53:22Z","timestamp":1775526802932,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"IMI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.vaccine.2021.05.059","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T08:27:08Z","timestamp":1622708828000},"page":"3964-3973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Brand-specific influenza vaccine effectiveness estimates during 2019\/20 season in Europe \u2013 Results from the DRIVE EU study platform"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4157-1315","authenticated-orcid":false,"given":"Anke L.","family":"Stuurman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8180-3782","authenticated-orcid":false,"given":"Jorne","family":"Biccler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2437-7876","authenticated-orcid":false,"given":"Alexandre","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"D\u00edez-Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cintia","family":"Mu\u00f1oz Quiles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Nohynek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Riera-Montes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.05.059_b0005","unstructured":"DRIVE consortium. DRIVE \u2013 Development of Robust and Innovative Vaccine Effectiveness \u2013 Increasing understanding of influenza vaccine effectiveness in Europe. https:\/\/www.drive-eu.org\/ . Accessed 26 March 2020. https:\/\/www.drive-eu.org\/ Accessed: July 18, 2019."},{"key":"10.1016\/j.vaccine.2021.05.059_b0010","unstructured":"Committee for Medicinal Products for Human Use. Guideline on Influenza Vaccines - Non-clinical and Clinical Module. EMA\/CHMP\/BWP\/310834\/2012. London: Eur Med Agency; 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2016\/07\/WC500211324.pdf. Accessed 26 March 2020."},{"key":"10.1016\/j.vaccine.2021.05.059_b0015","unstructured":"DRIVE consortium. How to participate in DRIVE. https:\/\/www.drive-eu.org\/index.php\/partners\/how-to-participate-in-drive\/. Accessed: Oct 6, 2020."},{"key":"10.1016\/j.vaccine.2021.05.059_b0020","unstructured":"DRIVE consortium. Governance. https:\/\/www.drive-eu.org\/index.php\/governance\/. Accessed: May 14 2021."},{"key":"10.1016\/j.vaccine.2021.05.059_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2020.07.063","article-title":"Vaccine effectiveness against laboratory-confirmed influenza in Europe-Results from the DRIVE network during season 2018\/19","author":"Stuurman","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.05.059_b0030","unstructured":"Stuurman A, Riera M, Bollaerts K, Alexandridou M, Rizzo C, Baum U, et al. D7.4 Setting up brand-specific influenza vaccine effectiveness studies in Europe \u2013 results of the pilot season 2017\/18. 2018. https:\/\/www.drive-eu.org\/wp-content\/uploads\/2018\/12\/D7_4_Report-pilot-season-201718_v1.0.pdf .Accessed 26 March 2020."},{"key":"10.1016\/j.vaccine.2021.05.059_b0035","unstructured":"Stuurman A, Biccler J, Riera M, DeSmedt T, Bollaerts K, Rizzo C, et al. D7.6 Brand-specific influenza vaccine effectiveness in Europe Season 2019\/20. https:\/\/www.drive-eu.org\/wp-content\/uploads\/2020\/10\/D7.7.DRIVE_IVE_Study_Report_1920_Final.pdf. Accessed: October 12, 2020."},{"key":"10.1016\/j.vaccine.2021.05.059_b0040","unstructured":"Flu News Europe. 2019\/20 season overview https:\/\/flunewseurope.org\/."},{"key":"10.1016\/j.vaccine.2021.05.059_b0045","unstructured":"WHO. Recommended composition of influenza virus vaccines for use in the 2020-2021 northern hemisphere influenza season. https:\/\/www.who.int\/influenza\/vaccines\/virus\/recommendations\/2020-21_north\/en\/. Accessed: October 12, 2020."},{"key":"10.1016\/j.vaccine.2021.05.059_b0050","unstructured":"WHO. Recommended composition of influenza virus vaccines for use in the 2019-2020 northern hemisphere influenza season. https:\/\/www.who.int\/influenza\/vaccines\/virus\/recommendations\/2019_20_north\/en\/. Accessed: November 21, 2019."},{"key":"10.1016\/j.vaccine.2021.05.059_b0055","unstructured":"Rizzo C, Alfonsi V, Bollaerts K, Riera M, Stuurman A, Turunen T. D7.1 Core protocol for type\/brand-specific influenza vaccine effectiveness studies (test-negative design studies). 2018. https:\/\/www.drive-eu.org\/wp-content\/uploads\/2018\/12\/DRIVE_D7.1_Core-protocol-for-test-negative-design-studies_1.1.pdf Accessed 26 March 2020."},{"key":"10.1016\/j.vaccine.2021.05.059_b0060","unstructured":"Syrj\u00e4nen R, Baum U, Nohynek H, Levi M, Riera M, Bollaerts K, et al. D7.2 Core protocol for type\/brand-specific influenza vaccine effectiveness studies (tpopulation-based database cohort studies). 2018. https:\/\/www.drive-eu.org\/wp-content\/uploads\/2018\/12\/DRIVE_D7.2_Core-protocol-for-population-based-database-cohort-studies_V1.1.pdf . Accessed 26 March 2020."},{"key":"10.1016\/j.vaccine.2021.05.059_b0065","unstructured":"DRIVE consortium. Brand-specific influenza vaccine effectiveness in Europe Statistical Analysis Plan Season 2019\/20. https:\/\/www.drive-eu.org\/wp-content\/uploads\/2018\/12\/D7_4_Report-pilot-season-201718_v1.0.pdf. May 2020."},{"key":"10.1016\/j.vaccine.2021.05.059_b0070","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.vaccine.2016.01.002","article-title":"Seasonal influenza vaccine effectiveness estimates: Development of a parsimonious case test negative model using a causal approach","volume":"34","author":"Lane","year":"2016","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.05.059_b0075","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity Analysis in Observational Research: Introducing the E-Value","volume":"167","author":"Vanderweele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2021.05.059_b0080","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/ije\/dyaa097","article-title":"Commentary: Continuing the E-value\u2019s post-publication peer review","volume":"49","author":"Poole","year":"2020","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.05.059_b0085","unstructured":"NHS England. Implementing the Joint Committee on Vaccination and Immunisation advice on vaccines in the NHS annual seasonal flu vaccination programme and reimbursement guidance for 2020\/21. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2019\/12\/NHS-England-JCVI-advce-and-NHS-reimbursement-flu-vaccine-2020-21.pdf. Accessed: December 7, 2020."},{"key":"10.1016\/j.vaccine.2021.05.059_b0090","unstructured":"Public Health England. Surveillance of influenza and other respiratory viruses in the UK: Winter 2019 to 2020. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/895233\/Surveillance_Influenza_and_other_respiratory_viruses_in_the_UK_2019_to_2020_FINAL.pdf. Accessed: August 28, 2020."},{"key":"10.1016\/j.vaccine.2021.05.059_b0095","doi-asserted-by":"crossref","first-page":"2000153","DOI":"10.2807\/1560-7917.ES.2020.25.10.2000153","article-title":"Interim 2019\/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020","volume":"25","author":"Rose","year":"2020","journal-title":"Eurosurveillance."},{"key":"10.1016\/j.vaccine.2021.05.059_b0100","article-title":"Comparative effectiveness of influenza vaccines among US Medicare beneficiaries ages 65 years and older during the 2019\u201320 season","author":"Izurieta","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.05.059_b0105","doi-asserted-by":"crossref","first-page":"21044","DOI":"10.2807\/1560-7917.ES2015.20.8.21044","article-title":"Effectiveness of influenza vaccination programme in preventing hospital admissions, Valencia, 2014\/15 early results","volume":"20","author":"Puig-Barber\u00e0","year":"2015","journal-title":"Eurosurveillance."},{"key":"10.1016\/j.vaccine.2021.05.059_b0110","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.8.17-00318","article-title":"Influenza vaccine effectiveness in preventing hospitalisation of individuals 60 years of age and over with laboratory-confirmed influenza, Valencia Region, Spain, influenza season 2016\/17","volume":"23","author":"Mira-Iglesias","year":"2018","journal-title":"Eurosurveillance."},{"key":"10.1016\/j.vaccine.2021.05.059_b0115","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.vaccine.2015.01.069","article-title":"Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness","volume":"33","author":"Jackson","year":"2015","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.05.059_b0120","first-page":"2060","article-title":"Observational studies and the difficult quest for causality: lessons from vaccine effectiveness and impact studies","volume":"45","author":"Lipsitch","year":"2016","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.05.059_b0125","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/aje\/kww064","article-title":"Theoretical basis of the test-negative study design for assessment of influenza vaccine effectiveness","volume":"184","author":"Sullivan","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.05.059_b0130","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/aje\/kww063","article-title":"Invited commentary: beware the test-negative design","volume":"184","author":"Westreich","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.05.059_b0135","article-title":"The impact of selection bias on vaccine effectiveness estimates from test-negative studies","author":"Jackson","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.05.059_b0140","article-title":"Cohort study design for estimating the effectiveness of seasonal influenza vaccines in real time based on register data: The Finnish example","volume":"1403494818808635","author":"Baum","year":"2018","journal-title":"Scand J Public Health."},{"key":"10.1016\/j.vaccine.2021.05.059_b0145","doi-asserted-by":"crossref","DOI":"10.1186\/s12982-020-00091-z","article-title":"Mitigation of biases in estimating hazard ratios under non-sensitive and non-specific observation of outcomes\u2013applications to influenza vaccine effectiveness","volume":"18","author":"Baum","year":"2021","journal-title":"Emerging Themes in Epidemiology."},{"key":"10.1016\/j.vaccine.2021.05.059_b0150","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.15585\/mmwr.mm6937a6","article-title":"Decreased influenza activity during the covid-19 pandemic\u2014United States, Australia, Chile, and South Africa, 2020","volume":"69","author":"Olsen","year":"2020","journal-title":"Morb Mortal Wkly Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2100654X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2100654X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:57:34Z","timestamp":1759402654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2100654X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":30,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0264410X2100654X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.059","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brand-specific influenza vaccine effectiveness estimates during 2019\/20 season in Europe \u2013 Results from the DRIVE EU study platform","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}